Therapeutic | Talquetamab |
Target 1 | GPRC5D |
Heavy Chain 1 | QVQLVQSGAEVKKPGASVKVSCKASGYSFTGYTMNWVRQAPGQGLEWMGLINPYNSDTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARVALRVALDYWGQGTLVTVSS |
Light Chain 1 | DIQMTQSPSSLSASVGDRVTITCKASQNVATHVGWYQQKPGKAPKRLIYSASYRYSGVPSRFSGSGSGTEFTLTISNLQPEDFATYYCQQYNRYPYTFGQGTKLEIK |
100% seqID Fv 1 Structure | None |
99% seqID Fv 1 Structure | None |
95-98% seqID Fv 1 Structure | None |
Target 2 | CD3E |
Heavy Chain 2 | EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARHGNFGNSYVSWFAYWGQGTLVTVSS |
Light Chain 2 | QTVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNLWVFGGGTKLTVL |
100% seqID Fv 2 Structure | None |
99% seqID Fv 2 Structure | None |
95-98% seqID Fv 2 Structure | None |
Follow these links to our prediction tools:
Format | Bispecific mAb |
Isotype | G4 |
Highest Clinical Trial (Jan '20) | Phase-I |
Estimated Status (Jan '20) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2019 |
INN Year Recommended | 2020 |
Companies Involved | Genmab, Janssen Research & Development |
Conditions Approved | na |
Conditions Active | Multiple myeloma |
Conditions Discontinued | na |
Notes |